# A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

> **NCT05611671** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)** · enrollment: 280 (actual)

## Conditions studied

- Inflammatory Bowel Diseases
- Colitis, Ulcerative

## Interventions

- **DRUG:** MORF-057
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05611671
- **Lead sponsor:** Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-21
- **Primary completion:** 2024-11-28
- **Final completion:** 2026-08
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05611671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05611671, "A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05611671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*